AAV-Mediated CCR5 Binding Agents for HIV Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV treatment and prevention methods, such as antiretroviral therapy (ART), come with side effects and dosing challenges, and there is a need for more effective long-term suppression and pre-exposure prophylaxis (PrEP) regimens that target the CCR5 co-receptor to halt viral replication and prevent new infections.
Innovation Solution
Recombinant adenovirus-associated viral vectors (rAAV) are used to deliver CCR5 binding agents with increased effector function and circulation half-life, specifically designed with human IgG Fc amino acid substitutions like M428L and N434S, to effectively target and occupy CCR5 receptors on CD4+ T cells, providing prolonged receptor occupancy and viral suppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiretroviral therapy (ART) is used to suppress viral replication, then long-term viral suppression is achieved, but unwanted side effects occur that reduce adherence
Solution Approach 1:
The patent extracts the essential function of ART (viral suppression through CCR5 blockade) while removing the harmful side effects by using a targeted monoclonal antibody approach rather than broad-spectrum antiretroviral drugs. The antibody specifically binds to CCR5 to prevent HIV entry without interfering with other metabolic processes that cause ART side effects.
Solution Approach 2:
The patent changes the pharmacokinetic parameters of the therapeutic agent by engineering the Fc region of the antibody with mutations (M428L, N434S, L234A, L235A, S131C) that extend circulation half-life and enhance effector functions, allowing for less frequent dosing and improved adherence while maintaining effective viral suppression.
2Reliability
If CCR5 binding agents are administered frequently to maintain receptor occupancy, then viral suppression is maintained, but dosing complexity and patient burden increase
Solution Approach 1:
The patent fundamentally changes the half-life parameter of the CCR5 binding agent from days to months through Fc region engineering. The mutations M428L and N434S enhance binding to the neonatal Fc receptor (FcRn), extending circulation half-life to greater than 60 days, enabling monthly or even quarterly dosing while maintaining sustained CCR5 receptor occupancy.
Solution Approach 2:
The patent ensures continuous therapeutic action through the extended half-life of the engineered antibody, which maintains effective CCR5 blockade continuously over months rather than requiring repeated dosing. The sustained presence of the antibody in circulation ensures uninterrupted viral suppression without gaps that would require frequent re-dosing.
3Reliability
If standard CCR5 antibodies are used, then HIV entry is blocked, but circulation half-life is limited reducing effectiveness
Solution Approach 1:
The patent applies multiple Fc region mutations (M428L, N434S, L234A, L235A, S131C) that collectively enhance the antibody's interaction with FcRn and modify effector functions. These parameter changes in the Fc region extend circulation half-life from weeks to months while simultaneously enhancing antiviral effector functions such as ADCP and CDC, creating a dual benefit.
Solution Approach 2:
The patent creates a composite therapeutic agent by combining the antigen-binding domain (which provides HIV entry blockade) with an engineered Fc region (which provides extended half-life and enhanced effector functions). This composite structure integrates multiple functional properties into a single therapeutic molecule, achieving both prolonged persistence and potent antiviral activity.
Data Source
AI summary
The present disclosure provides recombinant adenovirus-associated viral vectors for the delivery of CCR5 binding agents with increased effector function and circulation half-life that are useful for treating and preventing HIV and methods of use thereof.